Nothing Special   »   [go: up one dir, main page]

SG11201600147TA - Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors - Google Patents

Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors

Info

Publication number
SG11201600147TA
SG11201600147TA SG11201600147TA SG11201600147TA SG11201600147TA SG 11201600147T A SG11201600147T A SG 11201600147TA SG 11201600147T A SG11201600147T A SG 11201600147TA SG 11201600147T A SG11201600147T A SG 11201600147TA SG 11201600147T A SG11201600147T A SG 11201600147TA
Authority
SG
Singapore
Prior art keywords
raf kinase
urea compounds
fused tricyclic
dimer inhibitors
tricyclic urea
Prior art date
Application number
SG11201600147TA
Inventor
Changyou Zhou
Guoliang Zhang
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of SG11201600147TA publication Critical patent/SG11201600147TA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28Oxygen atom
    • C07D473/30Oxygen atom attached in position 6, e.g. hypoxanthine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11201600147TA 2013-06-28 2014-06-27 Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors SG11201600147TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2013078338 2013-06-28
PCT/CN2014/080983 WO2014206343A1 (en) 2013-06-28 2014-06-27 Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors

Publications (1)

Publication Number Publication Date
SG11201600147TA true SG11201600147TA (en) 2016-02-26

Family

ID=52141106

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201600147TA SG11201600147TA (en) 2013-06-28 2014-06-27 Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors

Country Status (19)

Country Link
US (4) US9670203B2 (en)
EP (1) EP3013798B1 (en)
JP (4) JP6380861B2 (en)
KR (1) KR102272606B1 (en)
CN (2) CN105452223B (en)
AU (1) AU2014301816B2 (en)
BR (1) BR112015032539B1 (en)
CA (1) CA2916543C (en)
DK (1) DK3013798T3 (en)
EA (1) EA029412B1 (en)
ES (1) ES2686821T3 (en)
HK (1) HK1217485A1 (en)
IL (1) IL242973A0 (en)
MX (1) MX362582B (en)
NZ (1) NZ716392A (en)
PT (1) PT3013798T (en)
SG (1) SG11201600147TA (en)
WO (1) WO2014206343A1 (en)
ZA (1) ZA201600513B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
AR091424A1 (en) 2012-06-13 2015-02-04 Incyte Corp TRICYCLE COMPOUNDS REPLACED AS INHIBITORS OF RECEIVERS OF THE FIBROPLAST GROWTH FACTOR (FGFR)
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
MY181497A (en) 2013-04-19 2020-12-23 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
SG11201600147TA (en) * 2013-06-28 2016-02-26 Beigene Ltd Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors
EP3013797B1 (en) * 2013-06-28 2018-01-03 BeiGene, Ltd. Fused tricyclic amide compounds as multiple kinase inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3259269B9 (en) 2015-02-20 2020-03-04 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
WO2017100591A1 (en) 2015-12-09 2017-06-15 Luc Therapeutics Heteroaromatic nmda receptor modulators and uses thereof
WO2017100593A1 (en) 2015-12-09 2017-06-15 Luc Therapeutics Thienopyrimidinone nmda receptor modulators and uses thereof
WO2018119374A1 (en) 2016-12-22 2018-06-28 Cadent Therapeutics Nmda receptor modulators and uses thereof
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
DK3788047T3 (en) 2018-05-04 2024-09-16 Incyte Corp Solid forms of an FGFR inhibitor and methods of making the same
AU2019262579B2 (en) 2018-05-04 2024-09-12 Incyte Corporation Salts of an FGFR inhibitor
LT3830092T (en) 2018-08-03 2023-09-11 Novartis Ag Heteroaromatic nmda receptor modulators and uses thereof
JP2022500385A (en) 2018-09-10 2022-01-04 ミラティ セラピューティクス, インコーポレイテッド Combination therapy
CN111484489B (en) * 2019-01-25 2023-05-23 百济神州(北京)生物科技有限公司 Amorphous B-RAF kinase dimer inhibitors
CN111484488A (en) * 2019-01-25 2020-08-04 百济神州(北京)生物科技有限公司 Stable crystal form A of B-RAF kinase dimer inhibitor
TWI849043B (en) * 2019-01-25 2024-07-21 英屬開曼群島商百濟神州有限公司 Stable solid dispersion of a b-raf kinase dimer inhibitor, methods of preparation, and uses therefor
CN111484490B (en) * 2019-01-25 2024-07-09 百济神州有限公司 Method suitable for large-scale production of B-RAF kinase dimer inhibitor
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
KR20210142154A (en) 2019-03-21 2021-11-24 옹쎄오 DBAIT molecules in combination with kinase inhibitors for the treatment of cancer
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021072028A1 (en) * 2019-10-08 2021-04-15 The Brigham And Women's Hospital, Inc. Activators of heme regulated inhibitor kinase (hri)
JP2022552324A (en) 2019-10-14 2022-12-15 インサイト・コーポレイション Bicyclic heterocycles as FGFR inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
BR112022010664A2 (en) 2019-12-04 2022-08-16 Incyte Corp DERIVATIVES OF A FGFR INHIBITOR
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
DK4146348T3 (en) 2020-05-08 2024-09-30 Halia Therapeutics Inc INHIBITORS OF NEK7 KINASE
MX2022015410A (en) 2020-06-05 2023-03-13 Kinnate Biopharma Inc Inhibitors of fibroblast growth factor receptor kinases.
IL307258A (en) 2021-04-05 2023-11-01 Halia Therapeutics Inc Nek7 inhibitors
TW202304459A (en) 2021-04-12 2023-02-01 美商英塞特公司 Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
WO2022226182A1 (en) 2021-04-22 2022-10-27 Halia Therapeutics, Inc. Nek7 inhibitors
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2023240178A1 (en) * 2022-06-08 2023-12-14 Mapkure, Llc Methods of treating cancer with a b-raf inhibitor
US20240158394A1 (en) 2022-09-14 2024-05-16 Halia Therapeutics, Inc. Nek7 inhibitors
TW202421133A (en) * 2022-09-26 2024-06-01 美商馬布可爾公司 Combinations of a b-raf inhibitor, and an anti-egfr antibody for the treatment of cancer
WO2024081948A1 (en) * 2022-10-14 2024-04-18 Springworks Therapeutics, Inc. Combination for use in treating cancers

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100733D0 (en) * 2001-03-05 2001-03-05 Medivir Ab Non-nucleoside reverse transcriptase inhibitors
DE60324568D1 (en) * 2002-09-05 2008-12-18 Medivir Ab Nicht-nucleoside revers-transcriptase inhibitoren
EP1696920B8 (en) 2003-12-19 2015-05-06 Plexxikon Inc. Compounds and methods for development of ret modulators
CA2589779A1 (en) 2004-12-23 2006-06-29 F. Hoffmann-La Roche Ag Benzamide substituted imidazo- and pyrolo-pyridines as protein kinase inhibitors
RU2008127486A (en) * 2005-12-08 2010-01-20 Милленниум Фармасьютикалз, Инк. (Us) BICYCLIC COMPOUNDS WITH INHIBITOR ACTIVITY AGAINST KINASE
WO2007136572A2 (en) * 2006-05-15 2007-11-29 Merck & Co., Inc. Antidiabetic bicyclic compounds
AU2007294149A1 (en) 2006-09-06 2008-03-13 F. Hoffmann-La Roche Ag Heteroaryl derivatives as protein kinase inhibitors
WO2008079909A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
PE20121126A1 (en) 2006-12-21 2012-08-24 Plexxikon Inc PIRROLO [2,3-B] PYRIDINES COMPOUNDS AS KINASE MODULATORS
JP2010533729A (en) 2007-07-17 2010-10-28 プレキシコン,インコーポレーテッド Compounds and methods for kinase regulation, and adaptations therefor
GB0807609D0 (en) * 2008-04-25 2008-06-04 Cancer Rec Tech Ltd Therapeutic compounds and their use
JO3101B1 (en) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co Benzothiazole derivatives as anticancer agents
US20100197924A1 (en) 2008-12-22 2010-08-05 Millennium Pharmaceuticals, Inc. Preparation of aminotetralin compounds
US8791265B2 (en) 2010-01-27 2014-07-29 Nerviano Medical Sciences S.R.L. Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors
RS55196B1 (en) 2011-12-31 2017-01-31 Beigene Ltd Fused tricyclic compounds as raf kinase inhibitors
SG11201600147TA (en) * 2013-06-28 2016-02-26 Beigene Ltd Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors
EP3013797B1 (en) * 2013-06-28 2018-01-03 BeiGene, Ltd. Fused tricyclic amide compounds as multiple kinase inhibitors

Also Published As

Publication number Publication date
WO2014206343A1 (en) 2014-12-31
EP3013798A4 (en) 2017-02-08
US9920055B2 (en) 2018-03-20
US20160368914A1 (en) 2016-12-22
EP3013798B1 (en) 2018-06-27
JP2020143120A (en) 2020-09-10
AU2014301816A1 (en) 2016-02-18
KR102272606B1 (en) 2021-07-05
EA029412B1 (en) 2018-03-30
US20170233391A1 (en) 2017-08-17
JP6889311B2 (en) 2021-06-18
MX362582B (en) 2019-01-24
BR112015032539B1 (en) 2022-07-12
US10208038B2 (en) 2019-02-19
ZA201600513B (en) 2018-07-25
CA2916543C (en) 2023-03-14
BR112015032539A2 (en) 2017-07-25
KR20160039187A (en) 2016-04-08
CN109369671B (en) 2021-07-27
US10562899B2 (en) 2020-02-18
JP6380861B2 (en) 2018-08-29
HK1217485A1 (en) 2017-01-13
JP7207629B2 (en) 2023-01-18
NZ716392A (en) 2017-03-31
CA2916543A1 (en) 2014-12-31
MX2016000143A (en) 2016-06-15
AU2014301816B2 (en) 2017-06-01
DK3013798T3 (en) 2018-10-15
IL242973A0 (en) 2016-02-29
ES2686821T3 (en) 2018-10-22
US9670203B2 (en) 2017-06-06
CN109369671A (en) 2019-02-22
CN105452223A (en) 2016-03-30
US20180282326A1 (en) 2018-10-04
JP2018184438A (en) 2018-11-22
JP2021120411A (en) 2021-08-19
EA201690098A1 (en) 2016-06-30
PT3013798T (en) 2018-11-12
US20190144446A1 (en) 2019-05-16
EP3013798A1 (en) 2016-05-04
CN105452223B (en) 2018-10-02
JP2016523269A (en) 2016-08-08
JP6707584B2 (en) 2020-06-10

Similar Documents

Publication Publication Date Title
HK1217485A1 (en) Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors raf / raf
HK1210166A1 (en) Fused tricyclic amide compounds as multiple kinase inhibitors
ZA201603337B (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
HK1218512A1 (en) Heterocyclic compounds and their uses
HK1211578A1 (en) Amidoimidazopyridazines as mknk-1 kinase inhibitors mknk-1
HK1219939A1 (en) Tricyclic benzoxaborole compounds and uses thereof
HK1220363A1 (en) Heterocyclic compounds and their uses
EP2968331A4 (en) Pyrimidine compounds as kinase inhibitors
GB201309603D0 (en) Novel compounds and their use as kinase inhibitors
GB201305741D0 (en) Novel compounds and their use as kinase inhibitors